Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02766699 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM
A Phase 1 study, sponsored by Engeneic Pty Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02766699: Completed Phase 1 study, sponsored by Engeneic Pty Limited.
NCT02766699 is a Phase 1 study that has completed, run by Engeneic Pty Limited. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02766699, a Phase 1 study, has completed, sponsored by Engeneic Pty Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies. The study will also examine the body's immune response to EGFR(V)-EDV-Dox and assess if it is effective in the treatment of patients with recurrent glioblastoma multiforme (GBM).
Primary Outcome
Recording of adverse Events (AE's) and clinically significant changes in vital signs, physical and neurological examinations, cardiac tests, radiological imaging inc. CT scan (Day 27/28) and clinical laboratory tests.
Interventions
- DRUG EGFR(V)-EDV-Dox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-10-25 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 1 |
What the finished NCT02766699 record still lists
NCT02766699 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which EGFR(V)-EDV-Dox is the first listed.
NCT02766699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02766699 about?
NCT02766699 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM". The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies. The study will also examine the body's immune response to EGFR(V)-EDV-Dox and assess if it is effective in the treatment of pat...
What is the current status of trial NCT02766699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-10-25. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT02766699?
The interventions under investigation include: EGFR(V)-EDV-Dox (DRUG).
Who is sponsoring clinical trial NCT02766699?
This trial is sponsored by Engeneic Pty Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02766699's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI